relapsed adult aml
Showing 1 - 14 of 14
Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)
Active, not recruiting
- Relapsed Adult ALL
- Relapsed Adult AML
-
Changchun, Jilin, ChinaFirst Hospital of Jilin University
Nov 19, 2023
AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)
Not yet recruiting
- AML, Adult
- +4 more
- AzaCITIDine Oral Tablet
- Xospata
-
Amiens, France
- +19 more
Sep 1, 2023
Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level
Not yet recruiting
- Relapsed Adult AML
- Refractory AML
- Navitoclax Dose Level -1
- +10 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023
Relapsed Adult AML Trial in Germany (Venetoclax Oral Tablet)
Recruiting
- Relapsed Adult AML
- Refractory AML
- Venetoclax Oral Tablet
-
Augsburg, Germany
- +11 more
Jan 11, 2023
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia Trial in United States
Recruiting
- Relapsed Adult AML
- +2 more
- Specialty Palliative Care
- Primary Palliative Care
-
Boston, Massachusetts
- +3 more
Aug 12, 2022
Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- venetoclax combining chidamide and azacitidine (VCA)
-
Xiamen, Fujian, ChinaBing Xu
Aug 1, 2022
Acute Myeloid Leukemia, Relapsed Adult AML Trial in United States (Lintuzumab-Ac225, Venetoclax, Spironolactone)
Recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
-
Los Angeles, California
- +4 more
Feb 22, 2022
Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
- (no location specified)
Feb 22, 2022
Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)
Recruiting
- Immunotherapy
- +3 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 2, 2021
Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML Trial in Suzhou (CAHAG regimen, Placebo regimen)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- CAHAG regimen
- Placebo regimen
-
Suzhou, Jiangsu, ChinaThe First Affliated Hospital of Soochow University
Oct 10, 2021
Acute Myeloid Leukemia, Relapsed Adult AML, Relapsed Pediatric AML Trial (ivosidenib (AG-120))
Approved for marketing
- Acute Myeloid Leukemia
- +2 more
- ivosidenib (AG-120)
- (no location specified)
Jul 20, 2018
Hematologic Cancer, Relapse Leukemia, Relapsed Adult ALL Trial in Montreal (GLIDE)
Unknown status
- Hematologic Cancer
- +8 more
- GLIDE
-
Montreal, Quebec, CanadaCIUSSS d l'Est-de-l'Île-de-Montréal
Dec 4, 2017